Published in Immunotherapy Weekly, April 6th, 2005
The availability of SARS-CoV-specific mAbs "is important for the development of both diagnostic tools and treatment of infection," immunologists in Canada explained.
In their study, M.J. Gubbins and coauthors at the National Microbiology Laboratory in Winnipeg evaluated "nine monoclonal antibodies raised in immune mice, using highly purified, inactivated SARS-CoV as the inoculating antigen."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.